As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Spyglass Pharma, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 24.1%. 6 filings are on record since February 10, 2026 (Schedule 13D, February 17, 2026).
Who owns SpyGlass Pharma, Inc.?
Sell to companies like Spyglass Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: RA Capital Management, L.P. · Percent: 24.1% · SCHEDULE 13D
- · Holder: Srinivas Akkaraju · Percent: 6.3% · SCHEDULE 13G
- · Holder: New Enterprise Associates 17, L.P. · Percent: 22.2% · SCHEDULE 13D
- · Holder: Gilde Healthcare Holding B.V. · Percent: 6.57% · SCHEDULE 13D
- · Holder: Sands Frank M. · Percent: 7.8% · SCHEDULE 13G
Spyglass Pharma, Inc. has 6 Schedule 13D or 13G filings on record since 2026-02-10. 6 holders' latest filing reports 5% or more of common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 24.1% | 8,022,639 | SCHEDULE 13D, 2026-02-17 | 2026-02-09 |
| New Enterprise Associates 17, L.P. | 22.2% | 7,392,301 | SCHEDULE 13D, 2026-02-13 | 2026-02-09 |
| Vensana Capital I GP, LLC | 9.9% | 3,310,619 | SCHEDULE 13D, 2026-02-10 | 2026-02-09 |
| 7.8% | 2,500,012 | SCHEDULE 13G, 2026-02-13 | 2026-02-06 | |
| Gilde Healthcare Holding B.V. | 6.57% | 2,187,513 | SCHEDULE 13D, 2026-02-13 | 2026-02-09 |
| 6.3% | 2,109,953 | SCHEDULE 13G, 2026-02-17 | 2026-02-09 |
Holding shares or following this stake? See who's behind Spyglass Pharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Spyglass Pharma, Inc. and the records around it.
Spyglass Pharma, Inc. elsewhere on the record
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Gilde Healthcare Holding B.V. also filed stake reports on 2 other companies: Shoulder Innovations, Inc. (Aug 2026), Mobia Medical, Inc. (May 2026)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Watch Spyglass Pharma, Inc.
Get an email when Spyglass Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Spyglass Pharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Spyglass Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Spyglass Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Vensana Capital I GP, LLC
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Kirk Nielsen is a member of the Issuer's board of directors. In addition, Kirk Nielsen, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation policy, which …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-10; the filing has the rest
New Enterprise Associates 17, L.P.
The Funds acquired the Firm Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-13; the filing has the rest
Gilde Healthcare Holding B.V.
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Geoff Pardo, a partner at Gilde Healthcare, serves as a member of the board of directors of the Issuer. In addition, in his capacity as a director, Mr. Pardo may be entitled to receive cash compensation and equity compensation, including stock options, restricted stock units or other equity awards, pursuant to …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-13; the filing has the rest
RA Capital Management, L.P.
The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving from development-stage or commercial programs of the Issuer, or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer's business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including stockholders of the Issuer, …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-10 | Vensana Capital I GP, LLC | 9.9% | SCHEDULE 13D |
| 2026-02-13 | New Enterprise Associates 17, L.P. | 22.2% | SCHEDULE 13D |
| 2026-02-13 | Gilde Healthcare Holding B.V. | 6.57% | SCHEDULE 13D |
| 2026-02-13 | Sands Frank M. | 7.8% | SCHEDULE 13G |
| 2026-02-17 | RA Capital Management, L.P. | 24.1% | SCHEDULE 13D |
| 2026-02-17 | Srinivas Akkaraju | 6.3% | SCHEDULE 13G |
Questions about who owns Spyglass Pharma, Inc.
Who owns Spyglass Pharma, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Spyglass Pharma, Inc.: RA Capital Management, L.P. (24.1%, Schedule 13D, filed 2026-02-17), New Enterprise Associates 17, L.P. (22.2%, Schedule 13D, filed 2026-02-13), Vensana Capital I GP, LLC (9.9%, Schedule 13D, filed 2026-02-10), Sands Frank M. (7.8%, Schedule 13G, filed 2026-02-13) and Gilde Healthcare Holding B.V. (6.57%, Schedule 13D, filed 2026-02-13); 1 more is listed above.
Who are the largest shareholders of Spyglass Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Spyglass Pharma, Inc. on this page are RA Capital Management, L.P. (24.1%), New Enterprise Associates 17, L.P. (22.2%) and Vensana Capital I GP, LLC (9.9%).
When did RA Capital Management, L.P. buy into Spyglass Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D, filed 2026-02-17, reporting 24.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Spyglass Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 6, 2026 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| January 29, 2026 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| January 16, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| June 5, 2025 | Form D, private offering | $75M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Spyglass Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.